Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Fatemeh Etemadifar"'
Autor:
Masoud Etemadifar, Shadi Ghourchian, Nazanin Mahinparvar, Mehri Salari, Fatemeh Etemadifar, Yalda Nikanpour, Shahin Sanaei, Mojtaba Akbari
Publikováno v:
Acta Medica Iranica, Vol 57, Iss 8 (2020)
This study aimed to compare the efficacy of rituximab versus Cyclophosphamide on active secondary progressive multiple sclerosis (SPMS). The randomized clinical trial was performed from 2015 to 2017 in multiple sclerosis (MS) clinics affiliated to Is
Externí odkaz:
https://doaj.org/article/e4f007b3a4a74e729e945b7831199ac6
Autor:
Masoud Etemadifar, Mohsen Janghorbani, Mohammad Mehdi Koushki, Fatemeh Etemadifar, Mahboobeh Fereidan Esfahani
Publikováno v:
International Journal of Preventive Medicine, Vol 5, Iss 11, Pp 1379-1386 (2014)
Background: The aim of this study was to estimate the conversion rate from radiologically isolated syndrome (RIS) to definite multiple sclerosis (MS). Methods: During a mean (standard deviation [SD]) follow-up period of 17.4 (5.4) (range 8-29) month
Externí odkaz:
https://doaj.org/article/a9f8487a4ace4708b14589fc3ac9dc90
Publikováno v:
Journal of Research in Medical Sciences, Vol 17, Iss 9, Pp 828-833 (2012)
Background: The efficacy of mitoxantrone induction therapy in rapidly worsening multiple sclerosis (MS) is well established. Plasma exchange is also applied as an adjuvant in exacerbations of relapsing MS. The aim of this study was to compare the eff
Externí odkaz:
https://doaj.org/article/5007fbee37fb4c1c807fa32b2c6073bb
Background Neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS) are inflammatory diseases of the central nervous system. Due to their many shared presentations, NMOSD misdiagnosis as MS is a rather common medical misconduct. Fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e877ec15be10f2bb751130ec7914da7
https://doi.org/10.21203/rs.3.rs-2416683/v1
https://doi.org/10.21203/rs.3.rs-2416683/v1
Autor:
Fatemeh Etemadifar, Mehri Salari, Mojtaba Akbari, S. Ghourchian, Masoud Etemadifar, Fatemeh Sabeti
Publikováno v:
Revue Neurologique. 176:113-117
Background Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) with varied prevalence rates among populations with different ethnic backgrounds. Therefore, studies done on minorities have shed more light on the risk
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49a96101d8d2d6684e62f10c968d2ffd
https://doi.org/10.1016/j.neurol.2019.04.004
https://doi.org/10.1016/j.neurol.2019.04.004
Publikováno v:
Multiple Sclerosis and Related Disorders. 27:127-130
Background Recent studies have suggested that anti-MOG antibodies and optic neuritis are associated and anti-MOG antibody positive patients have had better recoveries. The purpose of this study was to compare the clinical course and treatment outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::158a215dbac0c37fa7dd740697718c2b
https://doi.org/10.1016/j.msard.2018.10.013
https://doi.org/10.1016/j.msard.2018.10.013
Autor:
Shahin Sanaei, Nazanin Mahinparvar, Shadi Ghourchian, Mehri Salari, Fatemeh Etemadifar, Yalda Nikanpour, Mojtaba Akbari, Masoud Etemadifar
Publikováno v:
Acta Medica Iranica, Vol 57, Iss 8 (2020)
This study aimed to compare the efficacy of rituximab versus Cyclophosphamide on active secondary progressive multiple sclerosis (SPMS). The randomized clinical trial was performed from 2015 to 2017 in multiple sclerosis (MS) clinics affiliated to Is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7506a1f491b7785516b5ce80ffa017c1
https://acta.tums.ac.ir/index.php/acta/article/view/8096
https://acta.tums.ac.ir/index.php/acta/article/view/8096
Autor:
Hosein Nouri, Masoud Etemadifar, Newsha Sayahi, Mehri Salari, Parisa K Kargaran, Amirhossein Akhavan Sigari, Fatemeh Etemadifar, Sara Ebrahimi, Nahad Sedaghat
Publikováno v:
Multiple Sclerosis and Related Disorders. 54:103127
Differentiation of the demyelinating disorders of the CNS seems challenging in practice. Conus medullaris, the cone-shaped end of the spinal cord, is more involved in anti-MOG patients based on preliminary studies, a possibly helpful detail in its di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a94a25c1a9c038ae7020d8cc1576eeb
https://doi.org/10.1016/j.msard.2021.103127
https://doi.org/10.1016/j.msard.2021.103127